Evaluation of microscopic observation drug susceptibility assay for diagnosis of multidrug-resistant Tuberculosis in Viet Nam

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Minh Ha, Dang T ^a,b   Ngoc Lan, Nguyen T ^a   Wolbers, Marcel ^b   Kiet, Vo S ^b   Thanh Hang, Hoang T ^b   Duc, Nguyen H ^a   Huong, To M ^a   Bach, Vuong M ^a   Phuong Thao, Nguyen T ^a   Quyet, Tran V ^a   Bich Tuyen, Nguyen T ^a   Ha, Vo T ^a   Nho, Nguyen T ^a   Hoa, Dai V ^a   Hoang Anh, Phan T ^a   Dung, Nguyen H ^a   Farrar, Jeremy ^b   Caws, Maxine ^b  

^a Pham Ngoc Thach Hospital   (Viet Nam)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

Diagnosis; MDR TB; MODS; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ARTICLE; BACTERIAL LOAD; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; LOWENSTEIN JENSEN CULTURE; MALE; MICROSCOPIC OBSERVATION DRUG SUSCEPTIBILITY ASSAY; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLEX ALLELE SPECIFIC POLYMERASE CHAIN REACTION; MYCOBACTERIAL GROWTH INDICATOR TUBE; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; VIET NAM;

EID: 84860665374     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-49     Document Type: Article

References (32)

1. World Health Organisation Multidrug and extensively drug-resistant TB (M/XDR-TB). 2010 Global report on serveillance and response. WHO/HTM/TB/2010.3. 2010, Available at:. http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf. Accessed March 25, 2011, World Health Organisation.
2. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375(9728):1830-1843. 10.1016/S0140-6736(10)60410-2, 20488523.
3. World Health Organisation Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. 2007, WHO/HTM/TB/2007.379. Available at: http://whqlibdoc.who.int/hq/2007/WHO_HTM_TB_2007.379_eng.pdf. Accessed July 8, 2010, World Health Organisation.
4. World Health Organisation Strategic and Technical Advisory Group for Tuberculosis (STAG-TB). Report of the seventh meeting. 2007, Available at: http://www.who.int/tb/events/stag_report_2007.pdf. Accessed January 11, 2011, World Health Organisation.
5. World Health Organisation New laboratory diagnostic: Tools for Tuberculosis control. 2008, http://www.who.int/tdr/publications/documents/diagnostic-tool-tb.pdf Accessed April 18, 2010, World Health Organisation.
6. World Health Organisation Non-commercial culture and drug-susceptibility testing methods for screening of patients at risk of multi-drug resistant tuberculosis-Policy statement. 2010, Available at: http://www.stoptb.org/wg/gli/assets/documents/WHO%20Policy%20Statement%20on%20Non-commercial%20Culture%20and%20DST%20Methods%20FINAL%20March%202010.pdf. Accessed January 10, 2011, World Health Organisation.
7. Kremer K, van Soolingen D, Frothingham R, Haas WH, Hermans PW, Martin C, Palittapongarnpim P, Plikaytis BB, Riley LW, Yakrus MA, et al. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol 1999, 37(8):2607-2618. 85295, 10405410.
8. Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(10):688-698. 10.1016/S1473-3099(10)70165-1, 20813587.
9. World Health Organisation Strategic and Technical Advisory Group for Tuberculosis (STAG-TB). Report of the ninth meeting. 2009, Available at: http://www.who.int/tb/advisory_bodies/stag_tb_report_2009.pdf. Accessed January 10, 2011, World Health Organisation.
10. World Health Organisation Molecular line probe assay for rapid screening of patients at risk of multidrug-resistant. (MDR-TB). Policy Statement. 2008, Available at: http://www.who.int/tb/dots/laboratory/lpa_policy.pdf. Accessed June 12, 2010, World Health Organisation.
11. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363(11):1005-1015. 10.1056/NEJMoa0907847, 2947799, 20825313.
12. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, Venter WF, Duse A, Stevens W. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011, 8(7):e1001061. 10.1371/journal.pmed.1001061, 3144192, 21814495.
13. World Health Organisation Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. 2010, Available at: http://www.who.int/tb/laboratory/roadmap_xpert_mtb-rif.pdf. Accessed March 29, 2011, World Health Organisation.
14. Ejigu GS, Woldeamanuel Y, Shah NS, Gebyehu M, Selassie A, Lemma E. Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB. Int J Tuberc Lung Dis 2008, 12(3):332-337.
15. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, Sanchez E, Pinedo Y, Saravia JC, Salazar C, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006, 355(15):1539-1550. 10.1056/NEJMoa055524, 1780278, 17035648.
16. Moore DA, Mendoza D, Gilman RH, Evans CA, Hollm Delgado MG, Guerra J, Caviedes L, Vargas D, Ticona E, Ortiz J, et al. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings. J Clin Microbiol 2004, 42(10):4432-4437. 10.1128/JCM.42.10.4432-4437.2004, 522377, 15472289.
17. Moore D. MODS quality assurance. Available at: http://www.modsperu.org/MODS_QA.pdf. Accessed September 15, 2008. 2007.
18. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375(9729):1920-1937. 10.1016/S0140-6736(10)60359-5, 20488517.
19. Tran NB, Houben RM, Hoang TQ, Nguyen TN, Borgdorff MW, Cobelens FG. HIV and tuberculosis in Ho Chi Minh City, Vietnam, 1997-2002. Emerg Infect Dis 2007, 13(10):1463-1469. 2851533, 18257988.
20. World Health Organisation Global Tuberculosis Control. Epidemiology, strategy and financing (update). Available at: http://www.who.int/tb/publications/global_report/2009/update/tbu_9.pdf. Accessed March 3, 2010, World Health Organisation.
21. World Health Organisation Global tuberculosis control and patient care. A ministerial meeting of high M/XDR-TB burden countries. Beijing, China, 1-3 April 2009. Available at: http://www.who.int/tb_beijingmeeting/country_level/mdrtb_wprcountryprofile2007_vtn.pdf. Accessed July 7, 2010. In, World Health Organisation.
22. Ha DT, Lan NT, Kiet VS, Wolbers M, Hang HT, Day J, Hien NQ, Tien NA, An PT, Anh TT, et al. Diagnosis of pulmonary tuberculosis in HIV-positive patients by microscopic observation drug susceptibility assay. J Clin Microbiol 2010, 48(12):4573-4579. 10.1128/JCM.00687-10, 3008451, 20926704.
23. Dickinson B. Laboratory brocedure. BBL™ MGIT™ Mycobacteria Growth Indicator Tube 7 mL supplemented with BACTEC™ MGIT™ Growth Supplement, BBL™ MGIT™ PANTA™ Antibiotic Mixture. 2005, Available at: http://www.bd.com/ds/technicalCenter/inserts/L000180JAA%28201106%29.pdf. Accessed Feb 7, 2011.
24. Ha DT, Lan NT, Wolbers M, Duong TN, Quang ND, Thi Van Thinh T, Thi Hong Ngoc L, Thi Ngoc Anh N, Van Quyet T, Thi Bich Tuyen N, et al. Microscopic observation drug susceptibility assay (MODS) for early diagnosis of tuberculosis in children. PLoS One 2009, 4(12):e8341. 10.1371/journal.pone.0008341, 2791864, 20020056.
25. Honore-Bouakline S, Vincensini JP, Giacuzzo V, Lagrange PH, Herrmann JL. Rapid diagnosis of extrapulmonary tuberculosis by PCR: impact of sample preparation and DNA extraction. J Clin Microbiol 2003, 41(6):2323-2329. 10.1128/JCM.41.6.2323-2329.2003, 156509, 12791844.
26. World Health Organisation Guidelines for surveillence of drug resistance in tuberculosis. WHO/TB/2003.320-WHO/CDS/CSR/RMD/2003.3. 2003, Available at: http://whqlibdoc.who.int/publications/2003/9241546336.pdf. Accessed March 22, 2011, World Health Organisation.
27. Tho DQ, Ha DT, Duy PM, Lan NT, Hoa DV, Chau NV, Farrar J, Caws M. Comparison of MAS-PCR and GenoType MTBDR assay for the detection of rifampicin-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008, 12(11):1306-1312.
28. Tho DQ, Lan NT, Chau NV, Farrar J, Caws M. Multiplex allele-specific polymerase chain reaction for detection of isoniazid resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011, 15(6):799-803. 10.5588/ijtld.10.0599, 21575302.
29. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009, 13(11):1320-1330.
30. Jorge Coronel MR, Luz C, David M. MODS - A USER GUIDE - Microscopic Observation drug Susceptibility Assay. v12.114082008. Available at http://www.modsperu.org/MODS_user_guide.pdf. Accessed Jan 13 rd 2009, vol. v12.114082008. Lima - Peru; 2008.
31. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 2006, 55(Pt 11):1527-1531.
32. Mello FC, Arias MS, Rosales S, Marsico AG, Pavon A, Alvarado-Galvez C, Pessoa CL, Perez M, Andrade MK, Kritski AL, et al. Clinical evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to isoniazid or rifampin. J Clin Microbiol 2007, 45(10):3387-3389. 10.1128/JCM.00580-07, 2045335, 17699652.